With holiday parties in full gear, it's that time of year that will eventually lead to people getting sick. Feeling ill after that Christmas or New Year's Eve party? If could be RSV. But how can you ...

The winter respiratory virus season is still in full swing, with Illinois under a "high" alert level from the Centers for Disease Control and Prevention. Among the viruses circulating most are ...

Respiratory Syncytial Virus or RSV is one of the most common respiratory viruses circulating today. Often thought of as only being dangerous to babies and toddlers due to how often child-related RSV ...

As fall approaches, so does respiratory syncytial virus or RSV season. This year, there are more options for those most susceptible to RSV, including a new vaccine and updated RSV vaccine guidance for ...

Doctors say RSV trends are returning to pre-pandemic levels. Some hospitals in the U.S. are seeing an increase in RSV and higher levels of "walking pneumonia" among young children despite overall ...

Far fewer babies went to the hospital struggling to breathe from RSV, a severe respiratory infection, after the debut of a new vaccine and treatment this season, according to an analysis published ...

During the first RSV season in which a maternal vaccine and a monoclonal antibody for infants were available, 72% of infants were immunized, this study found. Disparities in access to immunization ...

April 1 (Reuters) - The European Commission approved Pfizer's (PFE.N), opens new tab respiratory syncytial virus vaccine for the prevention of lower respiratory tract disease caused by RSV in adults ...

The Food and Drug Administration has approved giving GSK's vaccine for respiratory syncytial virus down to age 50 years old, to those who are at higher risk of severe RSV, the company said Friday, ...

In a recent final analysis of a phase 3 trial, the bivalent respiratory syncytial virus prefusion F (RSVpreF) vaccine maintained high efficacy and a favorable safety profile against RSV-associated ...

The FDA approved clesrovimab (Enflonsia) to prevent lower respiratory tract disease from respiratory syncytial virus (RSV) in infants born during or entering their first RSV season, drugmaker Merck ...

Please provide your email address to receive an email when new articles are posted on . In 2023, the FDA approved two new powerful tools to protect infants against RSV: a maternal vaccine and a ...